Skip to main content
NCBI home page
Cartilage logoLink to Cartilage
. 2023 Sep 19;16(1):89–99. doi: 10.1177/19476035231200336

METTL3 Regulates the m6A Modification of NEK7 to Inhibit the Formation of Osteoarthritis

Xiaochuan Xiong 1,*,✉, Hao Xiong 1,*, Jun Peng 1, Yingjie Liu 1, Yang Zong 1
PMCID: PMC11744591  PMID: 37724835

Abstract

Objective

Osteoarthritis (OA) is a common degenerative joint disease. The occurrence of OA slowly destroys the soft tissue structure of the patient’s joint. Severe cases could lead to disability. Current studies had shown that inhibition of chondrocytes pyroptosis could slow down the progression of OA. Our work aimed to explore the specific mechanisms and ways of regulating this process.

Design

In this work, the level of N6-methyladenosine (m6A) in clinical tissues was detected by ribonucleic acid (RNA) m6A dot blot. qRT-PCR (quantitative real-time polymerase chain reaction) was used to detect the messenger RNA (mRNA) expression level of m6A modified enzyme in clinical tissues. MTT (3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromid) and flow cytometry were used to detect the effect of sh-METTL3 (methyltransferase like 3) and NIMA-related kinase 7 (NEK7) transfection on chondrocytes pyroptosis in OA. Western blot was used to detect the protein expression levels of pyroptosis-related proteins. ELISA (enzyme-linked immunosorbent assay) was used to measure the protein concentration of inflammatory cytokines. The SRAMP online database was used to predict the m6A site of NEK7. HE staining was used to assess the progression of OA in mice.

Results

The level of m6A in clinical samples of OA patients was higher, and METTL3 was significantly higher expressed in clinical samples of OA patients. We provided evidence that low expression of METTL3 inhibited chondrocytes pyroptosis. In addition, Rescue experiments and in vivo experiments had shown that METTL3 in combination with NEK7 inhibited the progression of OA by promoting chondrocytes pyroptosis.

Conclusions

METTL3 regulates m6A modification of NEK7 and inhibits OA progression.

Keywords: METTL3, NEK7, osteoarthritis, pyroptosis, chondrocytes

Introduction

Osteoarthritis (OA) is a common bone and joint disease. The clinical manifestations of OA are joint redness, dysfunction, and joint deformity. Severe cases can even become disabled. 1 Statistics from the Incidence and Prevalence Database suggests that 355 million people suffer from arthritis worldwide, and predicts that the number will double by 2040. 2 The progression of OA is the result of a combination of factors, such as joint trauma, population aging, large base weight, and sedentary lifestyle. 3 At present, most of the diagnosis and treatment methods of OA are mainly aimed at relieving pain, reducing swelling, and improving joint function. 4 There are no effective drugs for the clinical treatment of OA. However, recent studies have found that targeted therapy based on the pathogenesis of OA to design personalized treatment processes was an effective clinical OA treatment scheme. 5 Therefore, we explored the pathogenesis of OA to find suitable therapeutic targets.

Pyroptosis is a kind of programmed cell death caused by inflammasome. 6 Pyroptosis is widely involved in the occurrence and development of cancer, cardiovascular disease, brain injury, and other diseases.7-10 Pyroptosis is caused by inflammasome. Pyroptosis of cells is mainly dependent on inflammatory caspase and GSDMs protein family. 11 The classic process of pyroptosis could be summarized as the activation of caspase1 by inflammasome (e.g., NLRP3) binding to ASC. Activated caspase1 spliced GSDMD (Gasdermin D). The release of GSDMD-N punctured the cell membrane. As the osmotic pressure of the cell changes, the cell swelled until the cell membrane bursts.12-14 When the cell membrane is broken, activated inflammatory cytokines, such as IL-1β (interleukin-1β), IL-18 (interleukin-18), IL-6 (interleukin-6), and TNF-α (tumor necrosis factor-α) are released. 15 Therefore, the pyroptosis process is often accompanied by a strong inflammatory response. 16 Further study of pyroptosis is helpful to understand its role in the occurrence and development of related diseases, which may provide innovative ideas for clinical treatment.

The NEK kinase family is a conserved serine/threonine kinase family that plays a crucial role in regulating signaling pathways in metabolic cells. 17 NIMA-related kinase 7 (NEK7) was the shortest member of the family (302 bp). 18 NEK7 participated in regulating various cellular biological behaviors. 19 Abnormal expression of NEK7 could lead to the increased number of mitotic cells, chromosome abnormalities, and programmed cell death. Studies have shown that NEK7 is involved in the formation and activation of NLRP3 inflammasome.20,21 In addition, NEK7 is the key regulatory protein of NLRP3 inflammasome involved in pyroptosis. 22 However, the specific regulatory mechanism and the complete molecular route of the pyroptosis process involved in NEK7 in OA have not been fully investigated.

N6-methyladenosine (m6A) is considered to be one of the main ways of RNA posttranscriptional modification. 23 NGS reveals that a third of RNA in mammals has 4 or so m6A modifications. 24 M6A modification also plays an important role in regulating RNA splicing, translation, stability, translocation, and higher structure. 25 The m6A modification process mainly relied on 3 types of m6A methylation modification enzymes: “writers” (methyltransferases: METTL3, METTL14 [methyltransferase like 14] and WTAP [Wilms tumor 1-associating protein]) are responsible for the catalysis of m6A modification. 26 “Erasers” are demethylase (ALKBH5 [alkylation repair homolog 5] and FTO [fat mass and obesity associated]). 27 “Readers” identify the targeted RNA modified by m6A. 28 Furthermore, m6A methylation has been reported to be involved in and influence the pyroptosis process. 29 However, the specific modification mode of m6A methylation on NLRP3 in OA has not been fully explained.

Therefore, our work aimed to explore the specific mechanism and regulation of m6A methylation modification of NEK7 during the progression of OA through in vitro and in vivo experiments. We hypothesized that METTL3 might act as the key enzyme in m6A methylation modification to promote chondrocytes pyroptosis and inhibit the formation of OA.

Materials and Methods

Cartilage Specimens Collection

Cartilage specimens were taken from patients in our hospital, who underwent Total Knee Arthroplasty (TKA) surgery. Normal cartilage tissue in the control group was taken from the knee joint of patients undergoing total hip replacement for femoral neck fractures. 30 The selected patients were all clinically diagnosed with OA. Patients with traumatic knee OA, rheumatoid arthritis, and infectious arthritis were excluded. All the enrolled patients were aware of the research purpose and specific procedure of the experiment before surgery. All participants signed informed consent. Our study has been approved by the ethics committee of our hospital.

Chondrocytes Culture

The cultivation method was as described above. 31 The collected cartilage tissue was cut into approximately 3 × 3 mm2 pieces with a sterile scalpel. The fragments were digested in 2% trypsin (Gibco, Darmstadt, Germany) for 30 minutes and co-incubated with collagenase for 16 hours. The product was filtered through a cellular sieve. The filtered cells were digested by DNA enzyme (Gibco) for 15 minutes. Primary chondrocytes were obtained after cells were centrifuged 3 times. The cells were grown in 20% Fetal Bovine Serum and 1% P/S Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12; Gibco). The culture conditions were 37°C and 5% CO2. Lipopolysaccharide (LPS; 5 µg/ml; Sigma-Aldrich, Merck, Darmstadt, Germany) was used to induce primary chondrocytes at 37°C for 12 hours to construct cell models of OA. The OA cell lines used in this study are the second to fifth generation.

Chondrocytes Transfection

Short hairpin RNA METTL3 (sh-METTL3), over expression NEK7 (NEK7), and their negative control (sh-NC, vector) were purchased from GenePharma (Shanghai, China). When the integration degree of chondrocytes was about 80%, Lipofectamine 2000 (Thermo Fisher Scientific, CA) was used to perform cell transfection. The mRNA expression levels of METTL3 and NEK7 were determined by qRT-PCR.

Quantitative Real-time Polymerase Chain Reaction

The Total RNA Extraction Kit (Solarbio, Beijing, China) was used to extract total RNA from cells and tissues. A Universal RT-PCR Kit (M-MLV; Solarbio) was used to perform reverse transcription. 2×SYBR Green PCR Mastermix (Solarbio) was used to perform qRT-PCR. Primers involved in this article were listed in Supplemental Table S1. The relative expression levels of related genes were calculated by 2−ΔΔCT.

Stabilization Assay

Actinomycin D (2 mg/ml; Merck, Darmstadt, Germany) was treated with chondrocytes at 0, 6, 12, 18, and 24 hours. The mRNA expression levels of NEK7 were measured by qRT-PCR.

Western Blot

ProteoPrep Total Extraction Sample kit (Merck) was used to extract total proteins from chondrocytes. The target protein of the total protein was isolated by SDS-PAGE (polyacrylamide gel electrophoresis) and PVDF (polyvinylidenefluoride; Merck), and finally detected by an ECL kit (Beyotime, Beijing, China). After adding luminescent solution, the E-Gel Imager (Thermo Fisher Scientific) was used for exposure photography, image processing, and analysis. The main antibodies used in this study include NLRP3 (ab263899; Abcam, Cambridge, UK), ASC (ab307560; Abcam), caspase1 (ab179515; Abcam), GSDMD (ab215203; Abcam), and GADPH (ab9485; Abcam).

Dual-luciferase Reporter Assay

Site-directed Mutagenesis Kit (Sangon Biotech, Shanghai, China) was used to perform site-directed mutagenesis kit. We used the online software SRAMP (http://www.cuilab.cn/sramp) to predict the m6A sites of NEK7. MUT (Mutation) and WT (Wild type) fluorescent expression vectors for site1, site2, site3, and site4 of NEK7 were obtained from Genepharma. MUT or WT fluorescence expression vectors were co-transfected with sh-NC or sh-METTL3 into chondrocytes. The luciferase Reporter Assay System (Promega, Beijing, China) measured luciferase activity 48 hours later.

Cell Pyroptosis Assays

FLICA 660 Caspase-1 Assay Kit (ImmunoChemistry Technologies, CA, USA) was used for cell pyroptosis assays. Active Caspase-1 was detected in MCF-7 and MDA-megabyte (MB)-453 cell lines as recommended by the manufacturer. At the same time, propyl iodide (PI; Life Technologies, CA, USA) was added. IP was used to label cells with membrane pores. The fluorescence intensity of the cells was analyzed by flow cytometry (CytoFLEX, CA). Average fluorescence intensity was quantified using FlowJo v10.8.1 (OR).

Cell Viability Assay

The MTT cell viability and proliferation assay kit (ScienCell, CA) was used to assess the cell viability of chondrocytes. The transfected cells were added with 20 µl MTT solution and incubated for 4 hours. Then 150 µl of DMSO was added to the cells. Finally, cell viability was measured at 490 nm by MultiskanFC microplate reader (Thermo Fisher Scientific).

RNA m6A Dot Blot Assays

Total RNA is heated and cooled rapidly. The cooled total RNA was dripped onto Immobilon-Ny+ nylon coil film (Yiqi, Shanghai, China) and blocked by purple diplomatic membrane. The membrane was co-incubated with m6A antibody (1:1000; Abcam) at 4°C for 12 hours. The membrane was then coupled with Immunoglobulin G (IgG; Beyotime Biotechnology, Shanghai, China) for 1 hour. Finally, the membrane was visualized by the Imaging System (Bio-Rad, Universal Hood II, CA).

RNA-Binding Protein Immunoprecipitation

RIP (RNA-binding protein immunoprecipitation) lysis buffer (Millipore, MA) was used to lyse chondrocytes, which were then left overnight at 4°C. RNA protein immune complexes were precipitated by protein A/G magnetic beads. RNA was purified and verified by qRT-PCR.

MeRIP-qPCR

The extraction steps for Total RNA are shown above. 3 µg Synaptic Systems (RIP) anti-m6A was mixed with 200 µg RNA for 2 hours and then A/G magnetic beads were added. 50 µl of immunoprecipitation reagent (Thermo Fisher Scientific) was used to elute RNA. The enrichment of immunoprecipitated RNA was detected by qRT-PCR.

Enzyme-linked Immunosorbent Assay

The IL-1β ELISA kit, IL-18 ELISA kit, IL-6 ELISA kit, TNF-α ELISA kit, and IL-10 ELISA kit (Abcam) were used to detect the protein concentration of inflammatory cytokines. Cells were collected and centrifuged at 1,000 g for 20 minutes. ELISA kits were used to detect inflammatory components in cell supernatant and mouse serum.

Construction of OA Mice Models

Twenty male healthy C57BL/6J mice (10 weeks) were purchased from the National Rodent Laboratory Animal Resources Center (Shanghai, China). All mice were raised and treated in accordance with the procedures set by the Animal Resource Center of our School of Medicine. We referred to the experiment of Xu and Xu. 32 Fifteen mice were randomly selected for medial meniscus (DMM) resection to establish mice models of OA knee joint. Sham operation was performed on mice in sham group. Two weeks after DMM operation, 10 mice were randomly selected and divided into 2 groups. Mice in both groups were injected weekly with 5 µg sh-METTL3 or sh-NC (GenePharma). Six weeks after surgery, knee joint specimens were collected for analysis.

Hematoxylin-Eosin Staining

The knee joint of mice was fixed, paraffin-embedded, and sliced. Mice knee sections were stained with hematoxylin and eosin. Cartilage tissues were further stained with safranine O/sodium acetate buffer. Olympus BX51 optical microscope was used to observe and stain the slices. The Olympus DP72 digital camera (Tokyo, Japan) was used to obtain the image.

Statistical Analysis

All data were presented as the means ± standard deviation. The data statistical significance analyses and statistical mapping were performed using Prism GraphPad 8.0 software. Data were analyzed using 1-way analysis of variance (ANOVA) and Student t test. P < 0.05 was considered statistically significant.

Results

High Levels of m6A Methylation in OA Patients

In order to explore the effect of m6A methylation on OA patients, we tested the level of m6A methylation and the mRNA level expression of m6A modification enzyme in clinical samples of OA patients. As shown in Figure 1A , the level of m6A methylation in OA patients was higher than that in the control group. Meanwhile, the expression of m6A modification enzyme METTL3 was significantly increased in OA patients (1.00 ± 0.04 vs. 2.47 ± 0.19, P < 0.001, Fig. 1B ). The above data indicated that the progression of OA was related to m6A methylation modification. We speculated that METTL3 is the key m6A modifying enzyme in this process.

Figure 1.

Figure 1.

Open in a new tab

M6A levels in OA patients. (A) M6A level in clinical samples of OA patients. (B) Expression of m6A modification enzymes (METTL3, METTL14, WTAP, FTO, and ALKBH5) in clinical samples. M6A = N6-methyladenosine; OA = osteoarthritis; METTL3 = methyltransferase like 3; METTL14 = methyltransferase like 14; FTO = fat mass and obesity associated; WTAP = Wilms tumor 1-associating protein; ALKBH5 = Alkylation repair homolog 5; mRNA = messenger RNA.

METTL3 Knock-down Inhibited Pyroptosis in OA Cell Models

To confirm the influence of METTL3 on the progression of OA, we reduced the expression of METTL3 in chondrocytes and established the OA cell model by LPS induction. As shown in Figure 2A , we detected successful transfection of sh-METTL3 in chondrocytes by qRT-PCR (1.00 ± 0.07 vs 0.25 ± 0.04, P < 0.001). Then we examined the cell function. The MTT experiment showed a significant decrease in cell viability in the OA group compared with the control group (100.00 ± 7.04 vs. 27.08 ± 3.19, P < 0.001). However, this was reversed by METTL3 silencing (25.92 ± 3.58 vs. 70.31 ± 4.05, P < 0.001, Fig. 2B ). Flow cytometry results in Figure 2C and D showed that METTL3 silencing decreased the pyroptosis rate in OA cell models (18.89 ± 0.42 vs. 5.84 ± 0.52, P < 0.001). In addition, the same trend was observed in the expression of pyroptosis-related proteins NLRP3, ASC, caspase1, and GSDMD ( Fig. 2I ). Similarly, ELISA results showed that the protein concentrations of inflammatory cytokines IL-1β (213.50 ± 12.42 vs. 159.8 ± 4.84, P = 0.006), IL-6 (270.70 ± 13.80 vs. 116.60 ± 11.64, P < 0.001), IL-18 (128.40 ± 10.41 vs. 51.47 ± 5.65, P < 0.001), and TNF-α (399.60 ± 20.70 vs. 208.70 ± 12.30, P < 0.001) were decreased with METTL3 knockdown ( Fig. 2E-H ). These results all showed the effect of METTL3 on OA pyroptosis. Low expression of METTL3 effectively inhibited pyroptosis during the progression of OA.

Figure 2.

Figure 2.

Open in a new tab

METTL3 was the key enzyme for m6A methylation modification of OA. (A) Transfection efficiency of sh-METTL3 was detected by qRT-PCR. (B) Cell viability was measured by MTT. (C and D) The pyroptosis efficiency was determined by flow cytometry. (E-H) ELISA was used to detect the protein concentrations of inflammatory cytokines IL-1β, IL-6, LI-18, and TNF-α. (I) The protein expression levels of pyroptosis-related proteins NLRP3, ASC, caspase1 and GSDMD were determined by Western blot. METTL3 = methyltransferase like 3; m6A = N6-methyladenosine; OA = osteoarthritis; sh-METTL3 = short hairpin RNA METTL3; qRT-PCR = quantitative real-time polymerase chain reaction; MTT = 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromid; ELISA = enzyme-linked immunosorbent assay; IL-1β = interleukin-1β; IL-6 = interleukin-6; IL-18 = interleukin-18; TNF-α = tumor necrosis factor-α; NLRP3 = NOD-like receptor thermal protein domain associated protein 3; GSDMD = gasdermin D; sh-NC = negative control; ASC = apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.

METTL3 Promoted m6A Methylation of NEK7

The activation of NLRP3 inflammasome by NEK7 has been repeatedly reported in Nature.20,33 This effect in turn affected the pyroptosis processes in which NLRP3 was involved. To further elucidate the completed pathway of pyroptosis in chondrocytes during the progression of m6A methylated OA, we analyzed the changes in NEK7 when METTL3 expression decreased in chondrocytes. According to MeRIP-qPCR, we found that m6A levels in NEK7 were significantly reduced when METTL3 was knockdown (1.00 ± 0.11 vs. 0.25 ± 0.03, P < 0.001, Fig. 3A ). Moreover, qRT-PCR analysis showed that the mRNA expression level of NEK7 was also decreased with METTL3 knockdown (1.00 ± 0.05 vs. 0.36 ± 0.03, P < 0.001, Fig. 3B ). This indicated the positive regulatory relationship between METTL3 and NEK7. RIP analysis confirmed that METTL3 can bind to NEK7 (IgG vs. METTL3, 0.10 ± 0.01 vs. 0.61 ± 0.03, P < 0.001, Fig. 3C ). The SRAMP online software predicted m6A sites of NEK7. We selected 4 sites with scores exceeding very high confidence for the site-specific mutation ( Fig. 4D and E ). The results of double fluorescence detection showed that the fluorescence activity of NEK7 was significantly decreased with site 4 (1.00 ± 0.09 vs. 0.32 ± 0.04, P < 0.001). However, this situation was reversed when corresponding sites were mutated ( Fig. 3F-I ). This result further confirmed the binding of METTL3 to NEK7.

Figure 3.

Figure 3.

Open in a new tab

Binding effect of METTL3 and NEK7. (A) The m6A level of NEK7 after METTL3 expression was reduced. (B) qRT-PCR was used to detect the mRNA expression level of NEK7 after transfection with shMETTL3. (C) RIP detected the targeting relationship between METTL3 and NEK7. (D and E) The binding site between METTL3 and NEK7 was detected by SRAMP online analysis software. (F-I) The binding of METTL3 to NEK7 was detected by double luciferin report assay. (J) The mRNA stability of NEK7 was determined by Actinomycin D assay. METTL3 = methyltransferase like 3; NEK7 = NIMA-related kinase 7; m6A = N6-methyladenosine; qRT-PCR = quantitative real-time polymerase chain reaction; mRNA = messenger RNA; sh-METTL3 = short hairpin RNA METTL3; sh-NC = negative control; WT = wild type; MUT = mutation.

Figure 4.

Figure 4.

Open in a new tab

METTL3 regulated m6A modification of NEK7 gene to promote pyroptosis. (A) qRT-PCR was used to detect the transfection efficiency of overexpressed NEK7. (B) Cell viability was measured by MTT. (C and D) The pyroptosis efficiency was determined by flow cytometry. (E-H) ELISA was used to detect the protein concentrations of inflammatory cytokines IL-1β, IL-6, LI-18, and TNF-α. (I) The protein expression levels of pyroptosis-related proteins NLRP3, ASC, caspase1, and GSDMD were determined by Western blot. METTL3 = methyltransferase like 3; m6A = N6-methyladenosine; NEK7 = NIMA-related kinase 7; qRT-PCR = quantitative real-time polymerase chain reaction; MTT = 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromid; ELISA = enzyme-linked immunosorbent assay; IL-1β = interleukin-1β; IL-6 = interleukin-6; IL-18 = interleukin-18; TNF-α = tumor necrosis factor-α; NLRP3 = NOD-like receptor thermal protein domain associated protein 3; GSDMD = gasdermin D; sh-NC = negative control; sh-METTL3 = short hairpin RNA METTL3; WT = wild type; MUT = mutation; ASC = apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.

In addition, when the expression level of METTL3 decreased, the stability of NEK7 also enhanced ( Fig. 3J ). These results all confirmed the complementary relationship between METTL3 and NEK7. In conclusion, METTL3 could bind to NEK7. METTL3 positively regulated the m6A methylation level and expression level of NEK7.

METTL3 Regulated the m6A Modification of NEK7 Gene to Promote OA Cell Model Pyroptosis

To further elucidate the mode of action of pyroptosis affected by METTL3/NEK7 axis, we analyzed the cases of pyroptosis after NEK7 overexpression. As shown in Figure 4A , we detected successful transfection of NEK7 in chondrocytes by qRT-PCR (1.00 ± 0.08 vs. 2.66 ± 0.14, P < 0.001). Then we examined the cell function. MTT assay results showed that overexpression of NEK7 inhibited the increase of OA cell viability induced by silencing METTL3 (240.40 ± 11.18 vs. 165.00 ± 7.27, P < 0.001, Fig. 4B ). Flow cytometry results showed that NEK7 overexpression contributed to the reduction of chondrocytes pyroptosis caused by METTL3 knockdown (6.47 ± 0.32 vs. 12.71 ± 1.04, P < 0.001, Fig. 4C and D ). In addition, the same trend was observed in the expression of pyroptosis-related proteins NLRP3, ASC, caspase1, and GSDMD ( Fig. 4I ). Similarly, overexpression of NEK7 increased the protein concentrations of inflammatory cytokines IL-1β (142.20 ± 8.52 vs. 195.50 ± 11.40, P = 0.002), IL-6 (125.60 ± 9.59 vs. 206.60 ± 11.82, P < 0.001), IL-18 (47.93 ± 4.72 vs. 94.79 ± 8.22, P < 0.001), and TNF-α (203.50 ± 6.17 vs. 311.00 ± 16.21, P < 0.001; Fig. 4E-H ). These results all showed that NEK7 promoted OA pyroptosis and the process was regulated by m6A methylation with METTL3 as the key enzyme.

Knockdown METTL3 Expression Inhibited the Progression of OA in Mice

To further explore the role of the METTL3/NEK7 axis in vivo, we constructed a mouse model of OA. HE staining was used to assess the progression of OA in mice. It was found that, compared with OA group and OA + sh-NC group, the synovial cells in sham group and OA+sh-METTL3 group were arranged in an orderly manner, with loose connective tissue and less inflammatory cell infiltration. This suggested that METTL3 knockdown effectively inhibited the progression of OA in mice ( Fig. 5A ). In addition, ELISA results showed that OA progression increased the concentrations of inflammatory cytokines IL-6 (9.24 ± 1.87 vs. 58.74 ± 4.53, P < 0.001) and TNF-α (19.20 ± 1.82 vs. 79.07 ± 4.61, P < 0.001) in mice. Nevertheless, METTL3 knockdown reversed this process (IL-6, 61.20 ± 3.16 vs. 32.41 ± 3.72, P < 0.001; Fig. 5B; TNF-α, 76.72 ± 5.52 vs. 42.29 ± 5.31, P < 0.001; Fig. 5D). The change of IL-10 concentration was opposite to that of IL-6 and TNF-α (89.80 ± 11.71 vs. 38.22 ± 5.89, P < 0.001; 38.89 ± 5.44 vs. 58.57 ± 7.91, P = 0.007; Fig. 5C ). These results all suggested that METTL3 knockdown alleviated the release of inflammatory cytokines caused by OA in mice. The results of HE staining and ELISA assay suggested that METTL3 inhibited the progression of OA in vivo.

Figure 5.

Figure 5.

Open in a new tab

Knockdown METTL3 expression inhibited the progression of OA in mice. (A) HE staining was used to detect inflammatory cells in mice. (B-D) The protein concentrations of tissue inflammatory cytokines IL-6, IL-10, and TNF-α were determined by ELISA. METTL3 = methyltransferase like 3; OA = osteoarthritis; IL-6 = interleukin-6; IL-10 = interleukin-10; TNF-α = tumor necrosis factor-α; ELISA = enzyme-linked immunosorbent assay; sh-NC = negative control; sh-METTL3 = short hairpin RNA METTL3; HE = Hematoxylin and Eosin.

Discussions

Recent studies have shown that the vitality of chondrocytes played a key role in the progression of OA. 34 Chondrocytes pyroptosis mediated the development of OA. 35 We aimed to analyze the ways and mechanisms that regulate chondrocyte pyroptosis during the progression of OA. Our study showed that NEK7 promoted OA cell model pyroptosis. Furthermore, this process was mediated by m6A methylation of METTL3.

OA is a common degenerative joint disease. The occurrence of OA would slowly destroy the soft tissue structure of the patient’s joint and even lead to disability in severe cases.1,2,36 The incidence of OA also increases as people’s lifestyle changes. 3 There are no effective drugs for the clinical treatment of OA. However, inhibition of pyroptosis in chondrocytes could slow the progression of OA, which has attracted widespread attention.37,38 Li et al. 39 found that P2x7-induced chondrocytes pyroptosis played a key role in promoting inflammatory responses and the development of OA. Yu et al. 40 found that Corni Fructus treated OA by inhibiting the pyroptosis process of chondrocytes. M6A is one of the main ways to regulate and modify RNA after transcription. This modification process is widely involved in a variety of cellular activities, including pyroptosis. 41 Our study found that high methylation of m6A occurred in clinical tissues when OA occurred. This was consistent with the results of Ren et al. 30 At the same time, they also found that METTL3 was highly expressed in the development of OA. This aroused our interest and we further analyzed the role of m6A methylation modification enzyme METTL3. On one hand, Chen et al. 42 found that m6A methylation that inhibited METTL3 inhibited the progression of OA. On the other hand, Liu et al. 43 found that METTL3-mediated m6A methylation of NLRP3 inflammatory promoted podocyte pyroptosis in diabetic nephropathy, thereby ameliorating kidney injury. We found the same mechanism of action in OA through in vitro and in vivo experiments. METTL3 was overexpressed due to the inflammatory response of OA. Inhibition of METTL3 expression promoted cell viability in OA cell models and inhibited pyroptosis processes of chondrocytes, and attenuated OA in mice.

NEK7 is a protein kinase that regulates the cell cycle. It exists widely in all kinds of life activities. 44 Sun et al. 45 found that knockdown NEK7 inhibited the progression of OA in mice. Our study complemented this mechanism with cell function experiments. We found that overexpression of NEK7 significantly promoted chondrocyte pyroptosis and inhibited the progression of OA. In addition, the binding and activation between NEK7 and the inflammasome NLRP3 have been reported in Nature many times.20,33 This effect affects pyroptosis through the formation of inflammasome complexes through the recruitment of ASCs and shear of caspase1.21,22,46 Our study also demonstrated the effect of overexpression of NEK7 on pyroptosis-related proteins (NLRP3, ASC, caspase1, and GSDMD) and inflammatory cytokines (IL-1β, IL-18, IL-6, IL-10, and TNF-α). Interestingly, we found a complementary relationship between NEK7 and METTL3 by double luciferin reporting and rescue experiments. These results complemented the molecular regulatory mechanisms of pyroptosis promoted by NEK7. METTL3 acted as the m6A methylation modifier of NEK7. METTL3 combined with NEK7 positively regulated the m6A methylation level and expression level of NEK7.

Our study suggested that METTL3 regulated NEK7 gene m6A modification and regulation of chondrocyte pyroptosis in the development of OA. However, there were still some limitations in this study. We just analyzed the role of METTL3-mediated m6A methylation in OA progression. It is still unclear which “reader” played a recognition role in OA progression. In the future, we will conduct more in-depth research to improve the molecular mechanism of m6A modification in OA.

Conclusion

In conclusion, our work revealed for the first time the mechanism by which METTL3 regulated the m6A modification of NEK7 gene to inhibit the progression of OA, which might provide a new understanding of the roles of m6A and NEK7 in OA.

Supplemental Material

sj-docx-1-car-10.1177_19476035231200336 – Supplemental material for METTL3 Regulates the m6A Modification of NEK7 to Inhibit the Formation of Osteoarthritis
sj-docx-1-car-10.1177_19476035231200336.docx (43.1KB, docx)

Supplemental material, sj-docx-1-car-10.1177_19476035231200336 for METTL3 Regulates the m6A Modification of NEK7 to Inhibit the Formation of Osteoarthritis by Xiaochuan Xiong, Hao Xiong, Jun Peng, Yingjie Liu and Yang Zong in CARTILAGE

Footnotes

Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by J.P., Y.L., and Y.Z. The first draft of the manuscript was written by X.X. and X.H. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgments and Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Shanghai Jiao Tong University–affiliated Sixth People’s Hospital.

Consent to Participate: Informed consent was obtained from all individual participants included in the study.

Consent to Publish: The authors affirm that human research participants provided informed consent for publication of the images in Figures.

Data Availability: The data sets used and/or analyzed during this study are available from the corresponding author on reasonable request.

ORCID iD: Xiaochuan Xiong Inline graphic https://orcid.org/0009-0000-3409-5050

Supplemental material for this article is available on the Cartilage website at http://cart.sagepub.com/supplmental.

References

  • 1. Jiang Y. Osteoarthritis year in review 2021: biology. Osteoarthritis Cartilage. 2022;30(2):207-15. [DOI] [PubMed] [Google Scholar]
  • 2. Foster NE, Eriksson L, Deveza L, Hall M. Osteoarthritis year in review 2022: epidemiology & therapy. Osteoarthritis Cartilage. 2023;31(7):876-83. [DOI] [PubMed] [Google Scholar]
  • 3. Lynskey SJ, Macaluso MJ, Gill SD, McGee SL, Page RS. Biomarkers of osteoarthritis—a narrative review on causal links with metabolic syndrome. Life (Basel). 2023;13(3):730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293-311. [DOI] [PubMed] [Google Scholar]
  • 5. Molnar V, Matišić V, Kodvanj I, Bjelica R, Jeleč Hudetz ŽD, Rod E, et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int J Mol Sci. 2021;22(17):9208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595. [DOI] [PubMed] [Google Scholar]
  • 8. Jia C, Chen H, Zhang J, Zhou K, Zhuge Y, Niu C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311-8. [DOI] [PubMed] [Google Scholar]
  • 9. Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, et al. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021;11(18):8813-35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Zheng X, Chen W, Gong F, Chen Y, Chen E. The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review. Front Immunol. 2021;12:711939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Du T, Gao J, Li P, Wang Y, Qi Q, Liu X, et al. Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med. 2021;11(8):e492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Zuo Y, Chen L, Gu H, He X, Ye Z, Wang Z, et al. GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy. Expert Rev Mol Med. 2021;23:e23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40(1):153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27(9):673-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. He X, Fan X, Bai B, Lu N, Zhang S, Zhang L. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacol Res. 2021;165:105447. [DOI] [PubMed] [Google Scholar]
  • 16. Yang W, Tao K, Zhang P, Chen X, Sun X, Li R. Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response. Biochem Pharmacol. 2022;195:114863. [DOI] [PubMed] [Google Scholar]
  • 17. Wang J, Chen S, Liu M, Zhang M, Jia X. NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases. Inflammopharmacology. 2022;30(4):1179-87. [DOI] [PubMed] [Google Scholar]
  • 18. Li Y-K, Zhu X-R, Zhan Y, Yuan W-Z, Jin W-L. NEK7 promotes gastric cancer progression as a cell proliferation regulator. Cancer Cell Int. 2021;21(1):438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Byrne MJ, Nasir N, Basmadjian C, Bhatia C, Cunnison RF, Carr KH, et al. Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine. Biochem J. 2020;477(8):1525-39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. 2023;613(7944):595-600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-kappaB signaling. Cell Death Dis. 2019;10(12):906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Sheng M, Weng Y, Cao Y, Zhang C, Lin Y, Yu W. Caspase 6/NR4A1/SOX9 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed fatty liver. Cell Death Discov. 2023;9(1):106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Rong D, Sun G, Wu F, Cheng Y, Sun G, Jiang W, et al. Epigenetics: roles and therapeutic implications of non-coding RNA modifications in human cancers. Mol Ther Nucleic Acids. 2021;25:67-82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Cao X, Geng Q, Fan D, Wang Q, Wang X, Zhang M, et al. M6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion. Mol Cancer. 2023;22(1):42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Zhou H, Yin K, Zhang Y, Tian J, Wang S. The RNA m6A writer METTL14 in cancers: roles, structures, and applications. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188609. [DOI] [PubMed] [Google Scholar]
  • 27. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608-24. [DOI] [PubMed] [Google Scholar]
  • 28. Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q, et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer Discov. 2021;11(2):480-99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Wang X, Li Q, He S, Bai J, Ma C, Zhang L, et al. LncRNA FENDRR with m6A RNA methylation regulates hypoxia-induced pulmonary artery endothelial cell pyroptosis by mediating DRP1 DNA methylation. Mol Med. 2022;28(1):126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Ren J, Li Y, Wuermanbieke S, Hu S, Huang G. N-methyladenosine (m6A) methyltransferase METTL3-mediated LINC00680 accelerates osteoarthritis through m6A/SIRT1 manner. Cell Death Discov. 2022;8(1):240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Zhou H, Shen X, Yan C, Xiong W, Ma Z, Tan Z, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate osteoarthritis of the knee in mice model by interacting with METTL3 to reduce m6A of NLRP3 in macrophage. Stem Cell Res Ther. 2022;13(1):322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Xu H, Xu B. BMSC-derived exosomes ameliorate osteoarthritis by inhibiting pyroptosis of cartilage via delivering miR-326 targeting HDAC3 and STAT1//NF-κB p65 to chondrocytes. Mediators Inflamm. 2021;2021:9972805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Andreeva L, David L, Rawson S, et al. . NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation. Cell. 2021;184(26):6299-6312.e22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Rim YA, Nam Y, Ju JH. The role of chondrocyte hypertrophy and senescence in osteoarthritis initiation and progression. Int J Mol Sci. 2020;21(7):2358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ebata T, Terkawi MA, Kitahara K, Yokota S, Shiota J, Nishida Y, et al. Macrophage-derived extracellular vesicles trigger noncanonical pyroptosis in chondrocytes leading to cartilage catabolism in osteoarthritis. Arthritis Rheumatol. 2023;75(8):1358-69. [DOI] [PubMed] [Google Scholar]
  • 36. Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022;18(5):258-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Li Z, Huang Z, Zhang H, Lu J, Tian Y, Piao S, et al. Moderate-intensity exercise alleviates pyroptosis by promoting autophagy in osteoarthritis via the P2X7/AMPK/mTOR axis. Cell Death Discov. 2021;7(1):346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. An S, Hu H, Li Y, Hu Y. Pyroptosis plays a role in osteoarthritis. Aging Dis. 2020;11(5):1146-57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Li Z, Huang Z, Zhang H, Lu J, Tian Y, Wei Y, et al. P2X7 receptor induces pyroptotic inflammation and cartilage degradation in osteoarthritis via NF-κB/NLRP3 crosstalk. Oxid Med Cell Longev. 2021;2021:8868361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Yu H, Yao S, Zhou C, Fu F, Luo H, Du W, et al. Morroniside attenuates apoptosis and pyroptosis of chondrocytes and ameliorates osteoarthritic development by inhibiting NF-kappaB signaling. J Ethnopharmacol. 2021;266:113447. [DOI] [PubMed] [Google Scholar]
  • 41. Liu L, Li H, Hu D, Wang Y, Shao W, Zhong J, et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer. 2022;21(1):32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Chen X, Gong W, Shao X, Shi T, Zhang L, Dong J, et al. METTL3-mediated m6A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression. Ann Rheum Dis. 2022;81(1):87-99. [DOI] [PubMed] [Google Scholar]
  • 43. Liu BH, Tu Y, Ni GX, Yan J, Yue L, Li ZL, et al. Abelmoschus manihotTotal flavones of ameliorates podocyte pyroptosis and injury in high glucose conditions by targeting METTL3-dependent m6A modification-mediated NLRP3-Inflammasome activation and PTEN/PI3K/Akt signaling. Front Pharmacol. 2021;12:667644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Richards MW, O’Regan L, Mas-Droux C, Blot JMY, Cheung J, Hoelder S, et al. An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9. Mol Cell. 2009;36(4):560-70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Sun W, Yue M, Xi G, Wang K, Sai J. Knockdown of NEK7 alleviates anterior cruciate ligament transection osteoarthritis (ACLT)-induced knee osteoarthritis in mice via inhibiting NLRP3 activation. Autoimmunity. 2022;55(6):398-407. [DOI] [PubMed] [Google Scholar]
  • 46. Lin Y, Luo T, Weng A, Huang X, Yao Y, Fu Z, et al. Gallic acid alleviates gouty arthritis by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. Front Immunol. 2020;11:580593. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sj-docx-1-car-10.1177_19476035231200336 – Supplemental material for METTL3 Regulates the m6A Modification of NEK7 to Inhibit the Formation of Osteoarthritis
sj-docx-1-car-10.1177_19476035231200336.docx (43.1KB, docx)

Supplemental material, sj-docx-1-car-10.1177_19476035231200336 for METTL3 Regulates the m6A Modification of NEK7 to Inhibit the Formation of Osteoarthritis by Xiaochuan Xiong, Hao Xiong, Jun Peng, Yingjie Liu and Yang Zong in CARTILAGE

Articles from Cartilage are provided here courtesy of SAGE Publications

RESOURCES